 |
recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1) |
|---|---|
| Trade Name | |
| Orphan Indication | Primary sclerosing cholangitis |
| USA Market Approval | USA |
| USA Designation Date | 2016-08-25 00:00:00 |
| Sponsor | Acorda Therapeutics, Inc.;420 Saw Mill River Road;Ardsley, New York, 10502 |
